Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 5
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by List, A. F. Articles by Knight, R. Search for Related Content PubMed Articles by List, A. F. Articles by Knight, R.

Abstract

Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study

H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Mayo Clinic, Rochester, MN; Univ of Rochester, Rochester, NY; St. Johannes Hosp, Duisberg, DE; Univ of MA, Worchester, MA; New York Cornell Medcl Ctr, New York, NY; Wake Forest Univ, Winston Salem, NC; Stanford Univ, Stanford, CA; Celgene Corp, Warren, NJ

5

Background: Interstitial deletion of chromosome 5q31 is the most common CTG abnormality in MDS characterized by TD-anemia and megakaryocyte dysplasia. In a phase I/II trial in cytokine-unresponsive MDS, CC-5013 (RevLimid) yielded sustained transfusion-independence (TI) with CTG remission in 10/11 pts with del5q31 (List et al, NEJM 2005). We report results of a multicenter Phase II study evaluating the efficacy of CC-5013 in TD-MDS pts with del5q31. Methods: Eligible pts had Low- or Int-1 risk MDS, TD-anemia (2U RBC/8 wks), ANC500/µl, and platelets50,000/µl. CC-5013 was given 10mg/d x21 po q4 wks [n=44] or 10mg daily [n=104] with dose as needed. IWG response was assessed after 24 wks with blinded central pathology and CTG review. Response: Among 148 pts with del5q31 (isolated, n=111; +other, n=37), median age was 71 (range, 37–95) with 66% females, confirmed TD-MDS in 146, mean MDS duration of 3.4 years (<1 to 20.7), and median RBC burden 5U/8 wks. Low/Int-1 MDS was confirmed in 122 pts (82%), with ineligible dx’s of higher risk MDS [7], AML or other malignancy [3], or inadequate specimen [15]. In an intent-to-treat analysis, TI (56 d RBC transfusion-free + 1g/dl Hgb) was achieved in 93 (64%) TD-pts (95% CI: 55%–71%) with a median 3.9/dl Hgb (1.1–11.4) and 4 wk interval to response (0.3–19 wks). Among confirmed Low/Int-1 pts, 80 (66%) achieved TI vs 13/25 (52%; p=0.184) with other dx. TI rate was greater in pts with isolated del5q (69% vs 49%; p=0.003). CTG response (50 abnl metaphases) was achieved in 76% of TI patients with 55% CTG CRs. Pathologic CR was documented in 32/110 (29%) evaluable pts. After a median follow-up of 9.3 mos (4.2 to 14.8+), the median response duration is not reached with only 10 responders (9%) failing. Neutropenia (39%) or thrombocytopenia (35%) was the most common adverse event necessitating tx interruption or dose . Nine patients progressed to RAEB±t [n=5] or AML [n=4], and 12 succumbed to disease complications [n=9] or neutropenic infection [n=3]. Conclusions: CC-5013 is highly effective in MDS pts with del5q31 with unprecedented hematologic and CTG remitting activity.

Author Disclosure

Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene Celgene

Abstract presentation from the 2005 ASCO Annual Meeting